Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Small Pharma Inc
V.DMT
Healthcare
Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of...
depression. It has a portfolio of clinical-stage dimethyltryptamine (DMT)-based assets, SPL026 and SPL028. It has a pipeline of proprietary preclinical assets. Its clinical-stage program, SPL026, a first-generation DMT molecule, has shown proof-of-concept for the potential treatment of MDD. In a Phase IIa study, IV SPL026 demonstrated a rapid and durable antidepressant effect, as well as a favorable safety and tolerability profile. Small Pharma is also advancing SPL028, a second-generation injectable deuterated DMT molecule, in a Phase I trial.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:DMT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
(1)
•••
HugoNorth2004
X
View Profile
View Bullboard History
Post by
HugoNorth2004
on Oct 31, 2023 7:36pm
Room to run
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression
...more
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Sep 26, 2023 9:24am
Positive top line Data
GlobeNewswireSmall Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major ...Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when
...more
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company
posted Dec 22, 2024 9:00am by
Voyageur Pharmaceuticals Ltd
-
|
Voyageur is securing supply chains in North America for barium, iodine and fullerene drug development and is aiming to gain efficiencies in production of contrast media products. The company anticipates this LOI will expand Voyageur’s project portfolio and diversify the Company’s product mix. The global contrast media market is valued at $6.3 billion with GE HealthCare projecting it will double over the next decade. ...read more
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Sep 25, 2023 3:14pm
Dawg & Pony
Coming up. Tight Lines All The Ripper Company Website: https://cybin.com TORONTO -- (Business Wire) Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical
...more
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Sep 25, 2023 2:15pm
Cybin & Small Pharma
Have both doubled since the announcement! There's a lot more room to run IMO. Silver Tiger (SLVR) next big mover IMHO. Tight Lines All Fish Ripper
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Sep 18, 2023 5:34pm
Pop goes the weasel
Sheesh, up another 2 1/2 cents and I'll be back at a break even, lol. Kind Regards To All Numb Nutz
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Aug 28, 2023 10:02am
Halt?
Canadian Investment Regulatory Organization Trading Halt - DMT 2023-08-28 09:29 ET - News Release VANCOUVER, BC, Aug. 28, 2023 /CNW/ - The following issues have
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 01, 2023 7:50am
New Press Release - Small Pharma to Present at Cowen's 43rd Annual Health Care Conference
Company will also host a cocktail reception on Tuesday, March 7 LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 15, 2023 7:50am
New Press Release - First Subject Dosed in Small Pharma's First-in-Human Phase I Clinical Trial with SPL028
SPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscularLONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”...
read article.
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Feb 04, 2023 11:01am
Small Pharma receives OK for 2 U.S. patents
Small Pharma receives OK for 2 U.S. patents 2023-02-01 09:59 ET - News Release Mr. George Tziras reports SMALL PHARMA ANNOUNCES UPDATE ON INTELLECTUAL PROPERTY PORTFOLIO WITH
...more
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Feb 04, 2023 11:00am
Small Pharma has Nov. 30 cash position of $22.7-million
Small Pharma has Nov. 30 cash position of $22.7-million 2023-01-25 12:03 ET - News Release Mr. George Tziras reports SMALL PHARMA REPORTS FISCAL THIRD QUARTER 2023 HIGHLIGHTS
...more
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Feb 01, 2023 10:39am
Corporate Presentation
https://smallpharma.com/wp-content/uploads/2023/01/Small-Pharma-Corporate-Presentation-25-Jan.pdf Kind Regards To All Gilly
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 01, 2023 7:50am
New Press Release - Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT)...
read article.
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Comment by
GillRipper
on Jan 30, 2023 2:51pm
RE:RE:Price Target Raised
https://www.medicalgold.ca/posts/top-psychedelic-clinical-trials-in-2023 Kind Regards To All Gilly
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Comment by
GillRipper
on Jan 27, 2023 3:30pm
RE:Price Target Raised
Looks like the companies share buy back bid (236k) sitting there at 13.5....JMO. Kind Regards To All Gilly
(100)
•••
GillRipper
X
View Profile
View Bullboard History
Post by
GillRipper
on Jan 26, 2023 1:36pm
Price Target Raised
https://efhuttongroup.bluematrix.com/links2/html/1c2b91ac-8826-4cd7-8bde-07899276d305 https://microdose.buzz/news/small-pharma-phase-2a-trial-results/ Kind Regards To All Gilly
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments